Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$14.21 USD
-0.39 (-2.67%)
Updated Apr 22, 2024 11:55 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Viridian Therapeutics, Inc. (VRDN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$38.14 | $46.00 | $25.00 | 166.71% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Viridian Therapeutics, Inc. comes to $38.14. The forecasts range from a low of $25.00 to a high of $46.00. The average price target represents an increase of 166.71% from the last closing price of $14.30.
Analyst Price Targets (14)
Broker Rating
Viridian Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 85.71%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/21/2024 | B. Riley Securities | Kalpit Patel | Strong Buy | Strong Buy |
3/20/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
2/29/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
2/28/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
2/28/2024 | LifeSci Capital | Rami Katkhuda | Strong Buy | Strong Buy |
2/1/2024 | BTIG | Julian Harrison | Strong Buy | Strong Buy |
11/14/2023 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
8/8/2023 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 14 |
Average Target Price | $38.14 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | -1.07 |